Ding Jingnuo, Zhao Weifeng
Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, JiangSu Province, 215000, People's Republic of China.
Cancer Manag Res. 2022 Sep 15;14:2735-2748. doi: 10.2147/CMAR.S373165. eCollection 2022.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors of the digestive system and has a 5-year overall survival rate of 14.1%. Many HCC patients are diagnosed at an advanced stage, and thus early screening is essential for reducing the mortality of HCC. In addition to commonly used detection indicators such as serum alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3) and abnormal prothrombin (protein induced by vitamin K absence II, PIVKA-II), liquid biopsy techniques have been demonstrated to have diagnostic value in HCC detection. Compared with invasive procedures, liquid biopsy can detect circulatory metabolites of malignant neoplasms. Liquid biopsy techniques can detect circulating tumor cells, circulating tumor DNA, circulating RNA and exosomes and have been used in the early screening, diagnosis and prognostic evaluation of HCC. This paper reviews the molecular biological characteristics and application of different liquid biopsy techniques, and aim to highlight promising biomarkers that may be feasible options for early-stage HCC evaluation to improve early screening in populations at high risk for HCC.
肝细胞癌(HCC)是消化系统最常见的恶性肿瘤之一,其5年总生存率为14.1%。许多HCC患者在晚期才被诊断出来,因此早期筛查对于降低HCC死亡率至关重要。除了常用的检测指标如血清甲胎蛋白(AFP)、甲胎蛋白的刀豆凝集素反应性部分(AFP-L3)和异常凝血酶原(维生素K缺乏诱导蛋白II,PIVKA-II)外,液体活检技术已被证明在HCC检测中具有诊断价值。与侵入性检查相比,液体活检可以检测恶性肿瘤的循环代谢产物。液体活检技术可以检测循环肿瘤细胞、循环肿瘤DNA、循环RNA和外泌体,并已用于HCC的早期筛查、诊断和预后评估。本文综述了不同液体活检技术的分子生物学特征及应用,旨在突出有前景的生物标志物,这些标志物可能是早期HCC评估的可行选择,以改善HCC高危人群的早期筛查。